
PNTG Stock Forecast & Price Target
PNTG Analyst Ratings
Bulls say
Pennant Gr is viewed favorably because its core home health and hospice franchise is posting strong organic growth and margin expansion, with 3Q26 revenue of $239.8 million, same-store home health Medicare admissions up 12.0%, hospice ADC up 13.0%, and adjusted EPS of $0.35. The recent ~9% sell-off appears tied to temporary senior living occupancy pressure, as occupancy only fell 60 bps year over year to 81.2% and was concentrated in two integration-heavy markets, while management expects recovery in 4Q. Longer term, the company’s decentralized M&A model, improving Southeast integration, and underappreciated managed care contracting opportunity support further earnings upside, especially as the integration shifts from transition to optimization.
Bears say
Pennant Gr is viewed negatively because integration headwinds in its transitioning assets could force management to halt incremental M&A, undermining a key growth lever after years of rapid expansion. Home Health and Hospice momentum may plateau while labor pressures intensify, driving margin contraction and leaving FY27E EBITDAR 5% to 10% below current estimates, with valuation multiples compressing to 10.7x to 11.4x. The outlook is further weakened by heavy dependence on Medicare-funded reimbursement, senior housing occupancy risk from supply headwinds, and execution risk in turning around underperforming assets and recovering from COVID-driven pressure.
This aggregate rating is based on analysts' research of Pennant Group Inc and is not a guaranteed prediction by Public.com or investment advice.
PNTG Analyst Forecast & Price Prediction
Start investing in PNTG
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Pennant Group Inc (PNTG) Forecast
PNTG Analyst Forecast & Price Prediction
Start investing in PNTG
Order type
Buy in
Order amount
Est. shares
0 shares